Fused heterocyclic kinase inhibitors
US7439246B2 · kind B2 · utility
20Cited by
35References
31Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 1, 2005 |
| Grant date | Oct 21, 2008 |
| Priority date | — |
| Expiry date | Jan 21, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
In general, the instant invention comprises compounds of Formulas I and IIincluding pharmaceutically acceptable salts thereof. The compounds of the invention are useful as protein kinase inhibitors and therefore are useful for treating cancer and other protein kinase mediated diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.